Apr 24 |
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
|
Apr 24 |
Actym Therapeutics Appoints Thomas Smart as CEO
|
Mar 28 |
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
|
Mar 22 |
J.P. Morgan cuts Precigen to underweight, cites burn rate
|
Mar 20 |
Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript
|
Mar 20 |
Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript
|
Mar 19 |
Precigen Inc (PGEN) Reports Full Year 2023 Financial Results
|
Mar 19 |
Recap: Precigen Q4 Earnings
|
Mar 19 |
Precigen GAAP EPS of -$0.39 misses by $0.31, revenue of $6.23M beats by $4.53M
|
Mar 19 |
Precigen Reports Full Year 2023 Financial Results and Business Updates
|